ARCUTIS BIOTHERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $7.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2026-08-05
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2026-06-30 was $5.10M, a 30.77% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2026-03-31 was $1.90M, a 171.43% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-12-31 was $1.90M, a 111.11% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-09-30 was $2.00M, a 122.22% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2025 was $8.50M, a 112.50% increase from fiscal 2024.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2024 was $4.00M, a 85.71% decline from fiscal 2023.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2023 was $28.00M, a 8.53% increase from fiscal 2022.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $25.80M, a 80.42% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $7.00M 10-Q · filed 2026-08-05 | $8.90M derived: sum of 3 quarters · filed 2026-08-05 | $10.90M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $1.90M 10-Q · filed 2026-05-06 | $3.80M derived: sum of 2 quarters · filed 2026-05-06 | $5.80M derived: sum of 3 quarters · filed 2026-05-06 | $9.70M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $1.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $3.90M derived: sum of 2 quarters · filed 2026-02-25 | $7.80M derived: sum of 3 quarters · filed 2026-08-05 | $8.50M 10-K · filed 2026-02-25 |
| 2025-09-30 | $2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $5.90M derived: sum of 2 quarters · filed 2026-08-05 | $6.60M 10-Q · filed 2025-10-28 | $7.50M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $3.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $4.60M 10-Q · filed 2026-08-05 | $5.50M derived: sum of 3 quarters · filed 2026-08-05 | $6.40M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $700.00K 10-Q · filed 2026-05-06 | $1.60M derived: sum of 2 quarters · filed 2026-05-06 | $2.50M derived: sum of 3 quarters · filed 2026-05-06 | $4.20M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $900.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $1.80M derived: sum of 2 quarters · filed 2026-02-25 | $3.50M derived: sum of 3 quarters · filed 2026-02-25 | $4.00M 10-K · filed 2026-02-25 |
| 2024-09-30 | $900.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $2.60M derived: sum of 2 quarters · filed 2025-10-28 | $3.10M 10-Q · filed 2025-10-28 | $9.00M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $1.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $2.20M 10-Q · filed 2025-08-06 | $8.10M derived: sum of 3 quarters · filed 2026-02-25 | $15.30M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $500.00K 10-Q · filed 2025-05-06 | $6.40M derived: sum of 2 quarters · filed 2026-02-25 | $13.60M derived: sum of 3 quarters · filed 2026-02-25 | $22.30M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $5.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $13.10M derived: sum of 2 quarters · filed 2026-02-25 | $21.80M derived: sum of 3 quarters · filed 2026-02-25 | $28.00M 10-K · filed 2026-02-25 |
| 2023-09-30 | $7.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $15.90M derived: sum of 2 quarters · filed 2024-11-06 | $22.10M 10-Q · filed 2024-11-06 | $27.70M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $8.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $14.90M 10-Q · filed 2024-08-14 | $20.50M derived: sum of 3 quarters · filed 2025-02-25 | $27.30M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $6.20M 10-Q · filed 2024-05-14 | $11.80M derived: sum of 2 quarters · filed 2025-02-25 | $18.60M derived: sum of 3 quarters · filed 2025-02-25 | $27.00M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $5.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $12.40M derived: sum of 2 quarters · filed 2025-02-25 | $20.80M derived: sum of 3 quarters · filed 2025-02-25 | $25.80M 10-K · filed 2025-02-25 |
| 2022-09-30 | $6.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $15.20M derived: sum of 2 quarters · filed 2022-11-08 | $20.20M 10-Q · filed 2022-11-08 | $22.80M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $8.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $13.40M 10-Q · filed 2022-08-04 | $16.00M derived: sum of 3 quarters · filed 2024-02-27 | $20.30M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $5.00M 10-Q · filed 2022-05-05 | $7.60M derived: sum of 2 quarters · filed 2024-02-27 | $11.90M derived: sum of 3 quarters · filed 2024-02-27 | $14.40M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $2.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $6.90M derived: sum of 2 quarters · filed 2024-02-27 | $9.40M derived: sum of 3 quarters · filed 2024-02-27 | $14.30M 10-K · filed 2024-02-27 |
| 2021-09-30 | $4.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $6.80M derived: sum of 2 quarters · filed 2021-11-04 | $11.70M 10-Q · filed 2021-11-04 | $12.90M derived: sum of 4 quarters · filed 2021-11-04 |
| 2021-06-30 | $2.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $7.40M 10-Q · filed 2021-08-05 | $8.60M derived: sum of 3 quarters · filed 2021-08-05 | $9.31M derived: sum of 4 quarters · filed 2021-08-05 |
| 2021-03-31 | $4.90M 10-Q · filed 2021-05-06 | $6.10M derived: sum of 2 quarters · filed 2021-05-06 | $6.81M derived: sum of 3 quarters · filed 2021-05-06 | $7.33M derived: sum of 4 quarters · filed 2021-05-06 |
| 2020-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-16 | $1.91M derived: sum of 2 quarters · filed 2021-02-16 | $2.43M derived: sum of 3 quarters · filed 2021-02-16 | $2.80M 10-K · filed 2021-02-16 |
| 2020-09-30 | $710.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $1.23M derived: sum of 2 quarters · filed 2020-11-05 | $1.60M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $523.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $890.00K 10-Q · filed 2020-08-11 | ||
| 2020-03-31 | $367.00K 10-Q · filed 2020-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |